Metabolomics Services Market to Surpass US$ 1,396.79 Million by 2030, Says Coherent Market Insights (CMI)
February 10, 2023 09:00 ET
|
CMI
Burlingame, Feb. 10, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global metabolomics services market is estimated to be valued at US$ 483.74 in 2022 and is expected to...
Cancer Biomarker Market was valued USD 12 billion in 2021 & it will grow at a CAGR of 18% till 2029 : GreyViews
December 15, 2022 11:00 ET
|
GreyViews
Pune India, Dec. 15, 2022 (GLOBE NEWSWIRE) -- The market has been studied for the below mentioned-segmentation and regional analysis for North America, Europe, Asia, South America, and Middle East...
Vocal Biomarkers Market Size Worth USD 1.91 Billion by 2030 at 17.50% CAGR – Report by Market Research Future (MRFR)
December 01, 2022 10:00 ET
|
Market Research Future
New York, USA, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Vocal Biomarkers Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Vocal Biomarkers Market...
Next Generation Cancer Diagnostics Market Size to Garner $29.7 billion by 2028 with 17.80% CAGR: Latest Industry Insight by Markets N Research
November 10, 2022 09:00 ET
|
Markets N Research
Chicago, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The report "Next Generation Cancer Diagnostics Market by Technology (NGS, LOAC, RT-PCR) Application (CTC, Biomarker), Cancer Type (Lung, Breast) – Global...
Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature
June 10, 2021 02:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal Nature New method is being used by Nucleome to unlock the...
Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board
May 25, 2021 02:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board Nucleome’s unique technology platform has the potential to discover precision therapeutics...
Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress
April 29, 2021 10:31 ET
|
Allarity Therapeutics A/S
- Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib - Poster provides new details of the DRP® companion diagnostic for dovitinib,...
Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results
February 10, 2021 16:05 ET
|
Fluidigm Corporation
Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million Fourth Quarter Product and Service Revenue Increased 26 Percent to $40.5 million Full Year Total Revenue Increased 18 Percent to...
Fluidigm to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
February 04, 2021 16:02 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
December 10, 2020 08:30 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase...